Robert A. Ingram Elected to Regeneron Board of Directors

           Robert A. Ingram Elected to Regeneron Board of Directors

PR Newswire

TARRYTOWN, N.Y., April 4, 2014

TARRYTOWN, N.Y., April 4, 2014 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc.
(NASDAQ: REGN) today announced that it has elected Robert A. Ingram to its
Board of Directors. Regeneron also announced that Dr. Eric Shooter, a
co-founder of the Company, is retiring from the Board after nearly 26 years of
service to Regeneron.

Mr. Ingram was nominated to become a member of Regeneron's Board by Sanofi.
Under the terms of an investor agreement between Regeneron and Sanofi, Sanofi
gained the right to nominate a single independent director to the Regeneron
Board of Directors when it reached 20% ownership of Regeneron's total
outstanding common stock and Class A stock. Sanofi recently reached this
threshold.

"Bob Ingram is an experienced leader with a distinguished career in the
pharmaceutical industry," said P. Roy Vagelos, M.D., Chairman of the Regeneron
Board of Directors. "We are extremely pleased to add his expertise, which
spans many decades across many senior functions within the industry, to our
Board."

"I am delighted to be joining Regeneron at this exciting time in its history,"
said Mr. Ingram. "With three approved products, a broad pipeline of
antibodies, and multiple near-term commercial opportunities, I look forward to
helping Regeneron achieve its mission of delivering novel therapies to
patients with unmet medical needs."

Mr. Ingram is a General Partner at Hatteras Venture Partners, a venture
capital firm that invests in early stage life science companies. Prior to
Hatteras, Mr. Ingram was Chief Executive Officer and Chairman of
Glaxo/Wellcome. Mr. Ingram co-led the merger and integration that formed
GlaxoSmithKline. Upon reaching the mandatory retirement age of 60, Mr. Ingram
was asked to serve as the Vice Chairman, Pharmaceuticals at GSK. He remained
in this role until January 1, 2010, at which time he became Strategic Advisor
to the CEO of GlaxoSmithKline Plc. Mr. Ingram serves as the Lead Director of
Valeant Pharmaceuticals and Cree, Inc. He is also a member of the Board of
Directors of Edwards Lifesciences Corporation. He graduated from Eastern
Illinois University with a Bachelor's degree in Business Administration.

Regeneron also announced that Dr. Eric Shooter, a co-founder of the Company,
is retiring from the Board after nearly 26 years of outstanding service to
Regeneron. Dr. Shooter has been a Professor at Stanford University School of
Medicine since 1968 and was the founding Chairman of the Department of
Neurobiology at Stanford University School of Medicine in 1975 and served as
its Chairman until 1987. Dr. Shooter, a member of the National Academy of
Sciences, is best known for characterizing the protein known as Nerve Growth
Factor.

"Eric has been one of our longest serving non-employee directors and his
dedication to Regeneron over the past 26 years has been deeply appreciated,"
said Dr. Vagelos. "We have valued Eric's leadership, intellect, and
scientific acumen and would like to express our appreciation for his service."

About Regeneron Pharmaceuticals, Inc.

Regeneron is a leading science-based biopharmaceutical company based in
Tarrytown, New York that discovers, invents, develops, manufactures, and
commercializes medicines for the treatment of serious medical conditions.
Regeneron markets medicines for eye diseases, colorectal cancer, and a rare
inflammatory condition and has product candidates in development in other
areas of high unmet medical need, including hypercholesterolemia, oncology,
rheumatoid arthritis, asthma and atopic dermatitis. For additional
information about the company, please visit www.regeneron.com.

Regeneron Forward-Looking Statement

This news release includes forward-looking statements that involve risks and
uncertainties relating to future events and the future performance of
Regeneron, and actual events or results may differ materially from these
forward-looking statements. Words such as "anticipate," "expect," "intend,"
"plan," "believe," "seek," "estimate," variations of such words and similar
expressions are intended to identify such forward-looking statements, although
not all forward-looking statements contain these identifying words. These
statements concern, and these risks and uncertainties include, among others,
the nature, timing, and possible success and therapeutic applications of
Regeneron's products, product candidates, and research and clinical programs
now underway or planned, including without limitation EYLEA® (aflibercept)
Injection, sarilumab, alirocumab, and dupilumab; unforeseen safety issues
resulting from the administration of products and product candidates in
patients, including serious complications or side effects in connection with
the use of Regeneron's product candidates in clinical trials; the likelihood
and timing of possible regulatory approval and commercial launch of
Regeneron's late-stage product candidates and new indications for marketed
products; ongoing regulatory obligations and oversight impacting Regeneron's
research and clinical programs and business, including those relating to
patient privacy; determinations by regulatory and administrative governmental
authorities which may delay or restrict Regeneron's ability to continue to
develop or commercialize Regeneron's products and product candidates;
competing drugs and product candidates that may be superior to Regeneron's
products and product candidates; uncertainty of market acceptance and
commercial success of Regeneron's products and product candidates; the ability
of Regeneron to manufacture and manage supply chains for multiple products and
product candidates; coverage and reimbursement determinations by third-party
payers, including Medicare and Medicaid; unanticipated expenses; the costs of
developing, producing, and selling products; the ability of Regeneron to meet
any of its sales or other financial projections or guidance and changes to the
assumptions underlying those projections or guidance; the potential for any
license or collaboration agreement, including Regeneron's agreements with
Sanofi and Bayer HealthCare, to be cancelled or terminated without any further
product success; and risks associated with third party intellectual property
and pending or future litigation relating thereto. A more complete
description of these and other material risks can be found in Regeneron's
filings with the United States Securities and Exchange Commission, including
its Form 10-K for the year ended December 31, 2013. The reader is cautioned
not to rely on any forward-looking statements made by Regeneron. Regeneron
does not undertake any obligation to update publicly any forward-looking
statement, including without limitation any financial projection or guidance,
whether as a result of new information, future events, or otherwise.

Contact Information:
Manisha Narasimhan, Ph.D.     Peter Dworkin
Investor Relations              Corporate
                                 Communications
914.847.5126                    914.847.7640 
manisha.narasimhan@regeneron.com peter.dworkin@regeneron.com


SOURCE Regeneron Pharmaceuticals, Inc.

Website: http://www.regeneron.com
 
Press spacebar to pause and continue. Press esc to stop.